Stamford, Conn., July 01, 2021 – Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (s...
Stamford, Conn., June 14, 2021 – Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., today announced the publication of post-hoc analyses of data from a randomized, double‑blind, forced‑dose,...
Stamford, Conn., November 18, 2020 – Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced two recent online publications of studies related to the efficacy, safety and pharmacokineti...
Stamford, Conn., July 21, 2020 – Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., and the Prescription Drug Safety Network ("the Network") today announced the availability of a new interac...
Stamford, Conn., March 25, 2020 – Adlon Therapeutics L.P. today announced a publication in the Journal of Attention Disorders of data from a randomized, double-blind, fixed-dose study evaluating the e...
Stamford, Conn., January 30, 2020 – Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced today it has secured 2019 commercial formulary coverage from Express Scripts, a leading U.S. ...
Stamford, Conn., January 16, 2020 – Adlon Therapeutics L.P. and Purdue Pharma L.P. will present data from three studies evaluating PRC-063 at the 2020 American Professional Society of ADHD and Related...
Stamford, Conn., January 16, 2020 – Adlon Therapeutics L.P. and Purdue Pharma L.P. today announced that six posters highlighting PRC-063 data as well as research on real-world treatment patterns and p...
Stamford, Conn., July 30, 2019 – Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., today announced that Adhansia XR™ (methylphenidate hydrochloride) extended-release capsules CII, a central...
STAMFORD, Conn. – July 19, 2019 — We are pleased to announce that Christian Mazzi, MD, BSBA/BA, MBA will be joining us as President and Executive Medical Director, Adlon Therapeutics L.P. He wil...
Stamford, Conn., July 9, 2019 – Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., today announced it will join the Prescription Drug Safety Network (“the Network”) and will advance its comm...
Company accepting proposals for investigator-initiated research to evaluate outcomes associated with certain assessments of ADHD, and explore the burden and impact of ADHD on adolescent and adult pati...
In a simulated workplace environment study in adult patients with ADHD, Adhansia XR demonstrated statistically significant improvement in attention over placebo at one hour and at 16 hours post-dose S...
